Objective. To investigate the effects of achieving minimal disease activity (MDA) on the progression of subclinical atherosclerosis and arterial stiffness in patients with psoriatic arthritis (PsA).
INTRODUCTION
Incidence of myocardial infarction is increased in patients with psoriatic arthritis (PsA), rheumatoid arthritis (RA), and possibly ankylosing spondylitis compared to the general population (1) . Cardiovascular (CV) risk assessment is recommended for these patients at least once every 5 years, so that lifestyle advice and CV disease (CVD) preventive treatment can be initiated when indicated (2) . Screening for asymptomatic atherosclerotic plaques by carotid ultrasound has been recommended as part of the CV risk evaluation in patients with RA, as the presence of carotid plaques is associated with poor CVD-free survival and is strongly linked to a future diagnosis of acute coronary syndrome (3) . Similar to patients with RA, patients with PsA also had a greater burden of subclinical carotid atherosclerosis (4) (5) (6) (7) (8) . Increased intima-media thickening (IMT) significantly correlated with traditional risk factors (4-7) and disease-related parameters (4, 5) . Indeed, exposure to an increased burden of inflammation is associated with more severe atherosclerosis (9) and arterial stiffness (10) in patients with PsA, which may be mediated by traditional CV risk factors.
PsA may predispose patients to accelerated atherosclerosis through a number of mechanisms, including chronically elevated inflammatory cytokine levels, a higher prevalence of traditional CVD risk factors (11) , and the impact of pharmacotherapies. Markers of disease activity, as reflected by prior use of medication, a high erythrocyte sedimentation rate (ESR) at presentation, and evidence of radiologic damage, were associated with increased CV mortality in these patients (12) . Thus, it is possible that effective immunosuppression may interfere with the inflammation underlying both synovitis and atherosclerosis.
In PsA, criteria for minimal disease activity (MDA) have been developed and validated (13) . Achieving MDA by these criteria results in less radiographic damage in the long term (14) . While achieving MDA may result in significant benefits in articular disease (15) , little is known about its effect on extraarticular disease, including CVD risk. Previous studies linked the suppression of inflammation using anti-tumor necrosis factor (anti-TNF) agents with a favorable effect on carotid atherosclerosis (8, 16, 17) and arterial stiffness (18) in patients with PsA. However, whether this positive impact is specifically related to blocking TNF, or is due to a nonspecific effect from suppression of inflammation, cannot be differentiated. We hypothesized that abrogation of inflammation in PsA patients achieving MDA through a protocolized treatment strategy may prevent progression of subclinical atherosclerosis and arterial stiffness over a period of 2 years.
PATIENTS AND METHODS
Inclusion and exclusion criteria. A total of 101 consecutive patients with PsA attending the outpatient clinic of the Prince of Wales Hospital, age >18 years and fulfilling the Classification of Psoriatic Arthritis (CASPAR) criteria (19) , were recruited into this cohort study from April 2014 to October 2015. Patients were excluded if they met any 1 of the following criteria: 1) having a history of overt CVD (including myocardial infarction, angina, stroke, and transient ischemic attack), 2) taking antiplatelet agents (including aspirin, clopidogrel, etc.), hydroxymethylglutaryl-coenzyme A reductase inhibitors (statins), or angiotensin-converting enzyme inhibitors that would interfere with vascular outcomes, 3) having significant comorbidities, including severe renal impairment or severe deranged liver function, or 4) being a woman of childbearing potential who was pregnant, breastfeeding, or not using an effective method of contraception. Patients were not eligible if they were taking glucocorticoids at a dosage of >10 mg/day. Treatment protocol. All participants received 2 years of protocolized treatment (see Supplementary Figure 1 , available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley. com/doi/10.1002/art.40695/abstract), with the aim of achieving MDA. When a patient did not achieve the treatment goal after 4 months of therapy, the treatment was escalated to the next level according to the protocol, unless the patient declined further treatment or the toxic effects of the treatment precluded this approach.
The study was approved by the Ethics Committee of the Chinese University of Hong Kong, with written informed consent provided by all participants. The study was conducted in accordance with the Declaration of Helsinki.
Clinical assessments. Assessments conducted at each visit included the following: pain, the physician's and patient's global assessment, the tender joint count (TJC; 68 joints assessed) and swollen joint count (SJC; 66 joints assessed), the Maastricht Ankylosing Spondylitis Enthesitis Score (range 1-13) (20) , and the number of digits with dactylitis. The following instruments were used to measure joint and skin disease activity: the Bath Ankylosing Spondylitis Disease Activity Index (21), the Modified Health Assessment Questionnaire (M-HAQ) (22) , the Disease Activity Index for Psoriatic Arthritis (23), body surface area (BSA) affected by psoriasis, and the Psoriasis Activity and Severity Index (PASI) (24) .
MDA was used for the assessment of the treatment efficacy end point. The MDA criteria assess 7 domains, with the following cutoffs: TJC ≤1, SJC ≤1, enthesitis count ≤1, skin score ≤1 (or BSA ≤3%), function score ≤0.5 (measured by the HAQ) (25), patient's global assessment ≤20 on a 100-mm visual analog scale (VAS), and patient-reported pain ≤15 on a 100-mm VAS. If 5 of the 7 cutoffs for these domains were met, then the patient was classified as having MDA. Anthropomorphic measurements included body height, body weight, waist and hip circumferences, and blood pressure. The number of joints irreversibly damaged was assessed at baseline and annually. Patient information regarding menopausal status, smoking and drinking habits, history of diabetes mellitus, hypertension, dyslipidemia, overt CVD, and family history of CVD was obtained at baseline. Treatment history was retrieved from case notes or elicited during the clinical assessment.
Laboratory assessments and markers of inflammation. Laboratory assessments were conducted at baseline, every 4 months, and at the end of the study. These tests included complete blood cell count, liver and renal function tests, ESR, C-reactive protein level, fasting blood glucose level, lipid profile (total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglycerides), fibrinogen level, and uric acid level.
Carotid IMT and plaque. Carotid IMT and plaque were assessed at baseline, 12 months, and 24 months (7). Carotid IMT was measured by an experienced cardiologist (QS) who was blinded with regard to all clinical information, using a high-resolution B-mode EPIQ7 ultrasound machine (Philips) and a Philips L12-3 30 MHz linear vascular probe (broadband linear array transducer). The IMT was measured offline in the distal common carotid artery, carotid bulb, and proximal internal carotid artery using dedicated Philips Xcelera Cardiology Enterprise Viewer Client 4 software. The mean and maximal IMT values of 6 arterial segments were calculated for further analysis. Plaque was defined as a localized thick- ening of >1.2 mm that did not uniformly involve the whole artery. Progression of plaque was defined as an incident plaque in a segment without plaque before or an increased number of plaques in a segment. The reproducibility of IMT was 0.97 (7). The total plaque area (TPA) was measured as described previously (26) . The plane for measurement of each plaque was chosen by reviewing the video of the ultrasound scan to find the largest extent of plaque as seen on the longitudinal view. TPA was recorded as the sum of the areas of all plaques in the right and left carotid arteries.
Reading of the ultrasound scans obtained at baseline and at follow-up was performed concurrently by a single reader (ITC) who was aware of the temporal order of the images but was blinded with regard to the clinical data. The change in TPA was calculated by subtracting the baseline TPA from the follow-up TPA. The intraobserver intraclass correlation coefficient for TPA was 0.94 (27) .
Pulse wave velocity (PWV) and pulse wave analysis (PWA). Arterial stiffness was measured by PWV and the augmentation index value at baseline, 12 months, and 24 months (28) . PWA was performed using a SphygmoCor device (Vicorder; SMT Medical) with a tonometer probe at the right radial artery. The central aortic arterial pulse wave is transferred from the peripheral arterial pulse wave automatically. Since the augmentation index value for an individual patient varies by heart rate, it is standardized to a heart rate of 75 beats per minute. Ankle-brachial PWV was assessed noninvasively in subjects in the supine position, with a dedicated tonometry system (VP-2000; Omron Healthcare) as described previously. All PWA measurements were made by the same skilled operator (QS). Intraobserver reliability was 0.86 (28) .
Outcome measures. The primary outcome measure was the effect of achieving MDA at 12 months (MDA group) on the progression of subclinical atherosclerosis over a period of 24 months compared to those who did not achieve MDA (non-MDA group). Secondary outcome measures included 1) changes in arterial stiffness markers over a period of 24 months between the MDA group and the non-MDA group and 2) changes in subclinical atherosclerosis and arterial stiffness markers over a period of 24 months between patients who achieved sMDA (sMDA group) and those who did not (nonsMDA group). Sustained MDA was defined as having achieved MDA at every visit between month 12 and month 24 (i.e., months 12, 16, 20, and 24) . Additional analyses were performed to investigate the time-averaged achievement of MDA on vascular outcomes. The time-averaged achievement of MDA was determined by calculating the area under the curve of whether the patient had achieved MDA at each visit of the total follow-up period divided by the follow-up period.
Statistical analysis. Statistical analyses were performed using an SPSS version 24.0 software package.
Descriptive statistics, including frequency, percentage, mean and SD, and median and interquartile (IQR) range, were used for demographic and clinical variables. Comparisons in demographic and clinical characteristics at baseline and changes over 2 years between 2 groups were performed using the chi-square test, independent-sample t-test, and Mann-Whitney U test, depending on the distribution of data. Univariate analysis was performed to look for potential variables ( Table 1 ) that may predict the changes in vascular parameters, including IMT, PWV, augmentation index values, and TPA and progression of plaque. Chi-square tests were performed to analyze the association between the use of nonsteroidal antiinflammatory drugs (NSAIDs), conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), and biologic DMARDs (bDMARDs) and the achievement of MDA at each clinic visit. The vascular effects of achieving MDA at 12 months, achieving sMDA from month 12 through month 24, or time-averaged achievement of MDA were analyzed using multivariate linear or logistic regression models with adjustment for covariates (including the baseline covariates listed in Table 1 that we associated with progression in the vascular parameters from univariate analyses with a P value of less than 0.1, baseline vascular parameters, and the use of DMARDs and NSAIDs). A 2-tailed probability P value of less than 0.05 was considered significant.
RESULTS
A total of 101 patients were recruited; of these, 90 patients (mean ± SD age 50 ± 11 years, 57.8% male [n = 52], disease duration 9.9 ± 9.0 years) had a repeat carotid ultrasound and augmentation index, and were included in the final analysis for carotid plaque, IMT, and augmentation index progression, while 87 patients had a second PWV measurement (Figure 1) . Table 1 summarizes the clinical features and traditional CV risk factors of the patients at baseline and at month 24. Significant improvement in disease activity was observed in the whole cohort after 2 years. MDA was achieved by 15 (17%), 57 (63%), and 62 (69%) of patients at baseline, at 1 year, and at 2 years, respectively (Figure 2) . No statistically significant changes in traditional CV risk factors were observed, except for an increase in the Framingham Risk Score, which was most likely due to the increase in age.
Treatments. The use of csDMARDs increased from 57% at baseline and reached a peak of 75% at month 12, and then decreased to 69% at month 24. The use of bDMARDs increased from 18% at baseline to 31% at month 24 ( Figure 3A) . The use of NSAIDs decreased at baseline from 53% to 41% at month 24.
MDA and compliance with the protocol. The proportion of subjects reaching MDA increased progressively throughout the study period (Figure 2 ). On average, MDA was achieved in 53% of the visits. Treatment was escalated to the next level in 84% of visits when MDA was not met. The reasons for non-escalation of treatment are summarized in Supplementary MDA and treatment utilization. We next analyzed the relationship of MDA status and the use of medication at each visit separately. Altogether, there were a total of 769 patient visits. Among all the visits when patients were treated with bDMARDs (n = 216), a significantly higher proportion of them had achieved MDA (60% versus 40%; P = 0.005). Among all the visits when patients had achieved MDA (n = 397), fewer patients required treatment with NSAIDs (30% versus 70%; P < 0.001). Use of csDMARDs was not significantly associated with MDA (see Supplementary Achieving MDA at month 12 and progression of vascular parameters over 24 months. Fifty-seven of the subjects (63%) had achieved MDA at month 12 (MDA group). Baseline traditional CV risk factors were similar between the 2 groups (see Supplementary Table 2 , available at http://onlinelibrary.wiley.com/ doi/10.1002/art.40695/abstract). The MDA group had lower disease activity at baseline, probably because a higher proportion of patients was already taking bDMARDs. The prevalence of NSAID use was significantly lower (Supplementary Table 4) .
At month 24, the MDA group had significantly less progression as shown on the augmentation index, while the changes in mean and maximum IMT, PWV, TPA, and plaque progression were similar between the 2 groups ( Table 2) . Nonetheless, the differences in the change in the augmentation index Figure 1 . Study flow diagram. CASPAR = Classification of Psoriatic Arthritis Study Group; PsA = psoriatic arthritis; IHD = ischemic heart disease; CVA = cerebrovascular accident; ACEI = angiotensinconverting enzyme inhibitor; CAD = coronary artery disease; CT = computed tomography; cIMT = carotid intima-media thickness; Alx = augm entation index; PWV = pulse wave velocity. Figure 2 . Proportion of subjects achieving minimum disease activity across the study period. became insignificant after adjustment for baseline differences and csDMARD use throughout the 2 years (data not shown).
Achieving sustained MDA from month 12 to month 24 and progression of vascular parameters over 24 months. Forty-one patients (46%) achieved sMDA from month 12 to month 24. At baseline, patients in the sMDA group had lower disease activity, and a higher proportion of patients had already achieved MDA compared to those who did not achieve sMDA (see Supplementary Table 5 , available at http://onlinelibrary.wiley.com/doi/10.1002/art.40695/ abstract). A significantly higher proportion of subjects in the sMDA group were taking bDMARDs, while fewer patients were taking NSAIDs and csDMARDs (Figure 3) . Traditional CV risk factors were similar between the 2 groups, except that the sMDA group had fewer smokers (Supplementary Table 5 ). After 24 months, fewer patients in the sMDA group required NSAIDs ( Figure 3B ).
The vascular parameters were similar between the 2 groups at baseline (Table 2) . A total of 34 of 90 patients (38%) had plaque progression. Plaque progression was observed less frequently in the sMDA group than in the non-sMDA group, but the difference did not quite reach significance in univariate analysis. Regression analysis revealed that achieving sMDA was associ- 
DISCUSSION
This is the first longitudinal study to demonstrate that effective control of systemic inflammation in PsA patients who achieved sMDA was associated with less progression of subclinical atherosclerosis and arterial stiffness compared to those who did not achieve sMDA. The data in the study support the European League Against Rheumatism recommendation that disease activity should be controlled optimally in order to lower CVD risk in patients with PsA (2). After 2 years of protocol-driven, treat-to-target therapy, the proportion of patients achieving MDA increased from 16.7% at baseline to 63.3% at 12 months and to 68.9% at 24 months. The proportion of patients achieving MDA in our cohort at months 12 and 24 was similar to that in other observational studies in patients treated with anti-TNF agents (44-64%) (29) . A previous studies demonstrated that 60% of patients had achieved MDA on at least 1 visit and 34% had achieved MDA on consecutive visits for at least 12 months (30), which is similar to the results from the current study (55% and 46%, respectively). Data from the current study confirm that when using a treat-totarget strategy, MDA is indeed an achievable target, even in a health care system with limited resources.
The most important finding in this study is that long-term control of inflammation is essential in preventing the progression of subclinical atherosclerosis and arterial stiffness, independent of traditional CV risk factors. A single instance of achieving MDA at month 12 has no impact on the progression of subclinical atherosclerosis and vascular stiffness. Time- averaged achievement of MDA represented the percentage of time when the patient exhibited MDA throughout the study period, while sMDA demonstrated the prolonged control of disease activity over consecutive visits. These findings suggest that stable low disease activity over a prolonged period of time may have a significant protective effect against CVD in patients with PsA compared to those patients with intermittent flares. Previous studies have focused on the vascular effects of anti-TNF treatment in PsA, which were associated with reduced progression of carotid atherosclerosis (8, 16, 17) and arterial stiffness (18) , as well as with improvement in vascular inflammation (17) . A protective effect of anti-TNF agents, as compared to csDMARDs, was greater than when compared to no systemic therapy (17) . In fact, treatment with csDMARDs was associated with the progression of atherosclerosis (16, 17) . Those studies were unable to determine whether the vascular effects were due to suppression of inflammation or to the blockade of the specific pathways. In the present study, we observed that achieving sMDA had a protective effect on carotid atherosclerosis and arterial stiffness, a finding that was independent of the use of bDMARDs, suggesting that con- * TPA = total plaque area; OR = odds ratio; 95% CI = 95% confidence interval. † Adjusted for age, sex, baseline deformed joint count, physician's global assessment (PGA) score, plasma total triglyceride, total cholesterol, and low-density lipoprotein (LDL) cholesterol levels, use of biologic disease-modifying antirheumatic drugs (bDMARDs), and presence of carotid plaque at baseline. ‡ Adjusted for age, sex, baseline body mass index (BMI), visual analog scale pain score, patient's global assessment score, plasma total triglyceride, total cholesterol, and LDL cholesterol levels, and use of conventional synthetic DMARDs (csDMARDs). § Adjusted for disease duration, baseline C-reactive protein (CRP) level, Framingham Risk Score, use of nonsteroidal antiinflammatory drugs (NSAIDs), and use of bDMARDs throughout the year. ¶ Adjusted for age, sex, baseline CRP level, waist-to-hip ratio, plasma total cholesterol and, LDL cholesterol levels, use of NSAIDs, and maximum intima-media thickness (IMT). # Adjusted for age, sex, baseline abdominal obesity, and pulse wave velocity (PWV). ** Adjusted for age, sex, baseline augmentation index, and use of csDMARDs throughout the year.
trolling disease activity using various combinations of conventional and bDMARDs may be useful in improving CV risk in these patients. A previous study of PsA showed the superiority in achieving clinical outcomes of a treat-to-target strategy compared with routine care (15) . We investigated further to explore whether aiming at sMDA could lead to a better vascular outcome. A recent study showed that low disease activity (LDA) is sufficient to achieve a protective effect against CVD in RA (31). Apparently, remission defined as a Disease Activity Score in 28 joints (32) of <2.6 has no additional protective effect against CVD when compared to LDA. Data from that study, as well as from our study, showed that patients who are able to achieve and maintain MDA in PsA or LDA in RA during follow-up may be less likely to experience flares of uncontrolled, sustained, high systemic inflammation, which is a contributing factor to atherosclerosis and CVD. Patients with PsA with very active disease at diagnosis, with a poor treatment response and more frequent flares as a result, may form a subgroup within the PsA population that is particularly at risk for developing CVD, thereby significantly contributing to the excess CVD risk in this population. The idea that achieving sMDA reduces the risk of clinical CV events in PsA remains to be confirmed in large-scale prospective studies.
In both PsA and psoriasis patients, a higher burden of atherosclerotic plaques correlated with the measure of inflammatory burden, disease activity scores, and traditional risk factors (33) . A previous study demonstrated that in PsA patients, an increase in TPA was associated with the highest PASI score recorded in the first 3 years of follow-up (P = 0.02) (22) . The baseline median (IQR) PASI score in the current cohort was 3.4 (0.6-7.6), and most of the patients (71%) had mild psoriasis (PASI score <10). Therefore, our data on subclinical atherosclerosis applied mainly to patients with mild psoriasis. Another psoriatic disease cohort from Toronto with mild psoriasis (mean ± SD PASI score 1.9 ± 2.6) treated with anti-TNF agents also exhibited a reduced rate of atherosclerosis progression in men (17) . However, a pilot study in subjects with severe psoriasis vulgaris demonstrated reduced carotid IMT in patients without preexisting carotid plaques after anti-TNF therapy, suggesting that these findings may also be applicable to patients with severe psoriasis (34) . Future studies need to address the question of whether achieving MDA may prevent atherosclerosis progression in patients with severe psoriasis.
There are a few strengths in our study. To date, this is the first study to investigate a treat-to-target strategy to reduce CV risk. Also, this is one of the largest prospective studies to assess the impact of control of inflammation on 2 different phenotypic features of atherosclerosis in PsA, thereby providing insights about the effect of suppression of inflammation on early (arterial stiffness) and late (carotid plaque) phases of atherogenesis. Limitations of our study include the fact that, in Hong Kong, the cost of bDMARDs is not reimbursed by the government. As a result, most patients treated with bDMARDs paid the cost of the medication out-of-pocket. This may explain why some patients could not afford treatment with bDMARDs after treatment failure with csDMARDs. In PsA/psoriasis, limited evidence suggests that systemic therapies are associated with a decrease in all-CV-event risk (35) . Whether early initiation of bDMARDs, compared to csDMARDs, would improve CV outcome would need to be addressed in future studies. A second limitation of our study is the use of surrogate end points instead of actual CV events. There are few studies suggesting that carotid IMT (36) , plaque (37) , and PWV (38) are good surrogates of future CVD events, specifically in patients with RA. Nonetheless, we have reported a modest association between carotid atherosclerosis and coronary atherosclerosis in patients with PsA (39).
In conclusion, effective control of systematic inflammation by achieving sMDA was associated with less progression in subclinical atherosclerosis and arterial stiffness in patients with PsA. Our results strengthen the evidence supporting use of tight control (treat-to-target) strategies in daily clinical practice in order to achieve MDA in PsA patients, with the additional goal of reducing CVD risk.
